Saniona’s CSO to BioStock: “We are on track with SAN2219”

Saniona has taken a step forward within its epilepsy program by initiating the scale-up and manufacturing of toxicology batches for SAN2219. This move propels the program toward clinical studies, targeted for the first half of 2026. BioStock reached out to Chief Scientific Officer, Karin Sandager Nielsen, for a comment.

Read the full interview with Karin Sandager Nielsen at biostock.se:

https://www.biostock.se/en/2025/03/sanionas-cso-we-are-on-track-with-san2219/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/